AACR-FDA-NCI cancer biomarkers collaborative consensus report: Advancing the use of biomarkers in cancer drug development

Clinical Cancer Research

Volumn 16, Issue 13, 2010, Pages 3299-3318

  Khleif, Samir N ^a   Doroshow, James H ^a   Hait, William N ^b  

^a Johnson and Johnson Family of Companies   (United States)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADOPTION; BIOINFORMATICS; CANCER PATIENT; CELL LEVEL; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CLINICAL RESEARCH; CONSENSUS; DATA BASE; DIAGNOSTIC TEST; DRUG COST; DRUG DEVELOPMENT; DRUG EFFICACY; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HUMAN; INFORMED CONSENT; KNOWLEDGE; MEDICAL DOCUMENTATION; MEDICAL RESEARCH; MOTION; PATIENT CARE; POLICY; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; REIMBURSEMENT; REVIEW; SAFETY; STANDARD; VALIDATION PROCESS;

ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; SOCIETIES, MEDICAL; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VALIDATION STUDIES AS TOPIC;

EID: 77954241248     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0880     Document Type: Review

References (35)

1. Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov Today 2008;13:30-7.
2. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25:209-16.
3. Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 2008;14:5967-76.
4. Duffy MJ. Predictive markers in breast and other cancers: a review. Clin Chem 2005;51:494-503.
5. Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin Chem 2008;54:1770-9.
6. Gasparini G, Longo R, Torino F, Gattuso D, Morabito A, Toffoli G. Is tailored therapy feasible in oncology? Crit Rev in Oncol Hematol 2006;57:79-101.
7. Hayes DF. Prognostic and predictive factors revisited. Breast 2005; 14:493-9.
8. U.S. Food and Drug Administration. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. March 2004 [cited April 5, 2010]. Available from: http://www.fda.gov/downloads/ScienceResearch/ Special-Topics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ ucm113411.pdf.
9. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005;5:845-56.
10. Moore HM, Compton CC, Lim MD, Vaught J, Christiansen KN, Alper J. 2009 Biospecimen research network symposium: advancing cancer research through biospecimen science. Cancer Res 2009;69:6770-2.
11. National Cancer Institute. Office of Biorepositories and Biospecimen Research. National Cancer Institute best practices for biospecimen resources. June 2007 [cited March 26, 2010]. Available from: http://biospecimens.cancer. gov/global/pdfs/NCI-Best-Practices-060507.pdf.
12. Caboux E, Plymoth A, Hainaut P, editors. Common minimum technical standards and protocols for biological resource centres dedicated to cancer research, IARC Working Group Report 2. International Agency for Research on Cancer; 2007 [cited March 26, 2010], pp. 1-38. Available from: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk2/standardsBRC-1.pdf.
13. Organisation for Economic Co-Operation and Development. OECD best practices guidelines for biological resource centres. Paris: OECD Publishing; 2007 [cited March 26, 2010]. Available from: http://www.oecd.org/dataoecd/7/13/ 38777417.pdf.
14. Pitt KE, Campbell LD, Skubitz APN, Somiari SB, Sexton KC, Pugh RS, editors. International Society for Biological and Environmental Repositories. 2008 Best practices for repositories: collection, storage, retrieval and distribution of biological materials for research. Cell Preservation Technology 2008;6:3-58.
15. National Cancer Institute, Office of Biorepositories and Biospecimen Research. Summary: National Cancer Institute Biospecimen Best Practices Forum; November 5, 2007 [cited February 25, 2010]; Boston, MA. Available from: http://biospecimens.cancer. gov/practices/forum/boston2007/pdf/FINAL-11-05-07- NCI-BPs-Forum-Boston-Summary-Rev1-24-08-Ed.pdf.
16. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for reporting of diagnostic accuracy. Clin Chem 2003;49:1-6.
17. Haga SB, Beskow LM. Ethical, legal, and social implications of biobanks for genetics research. Adv Genet 2008;60:505-44.
18. Report of the Public Responsibility in Medicine and Research (PRIM&R) Human Tissue/Specimen Banking Working Group. March 2007 [cited February 25, 2010]. Available from: http://www.primr.org/uploadedFiles/PRIMR-Site-Home/ Public-Policy/Recently-Files-Comments/Tissue%20Banking%20White%20Paper%203-7- 07% 20final%20combined.pdf.
19. Irwin DA, Klenow PJ. Sematech: purpose and performance. Proc Natl Acad Sci U S A 1996;93:12739-42.
20. U.S. Food and Drug Administration. Drug-diagnostic codevelopment concept paper-draft. April 2005 [cited April 5, 2010]. Available from: http://www.fda.gov/downloads/Drugs/ScienceResearch/ResearchAreas/ Pharmacogenetics/UCM116689.pdf.
21. U.S. Food and Drug Administration. Table of valid genomic biomarkers in the context of approved drug labels [updated March 15 2010; accessed April 5, 2010]. Available from: http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ Pharmacogenetics/ucm083378.htm.
22. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
23. Paik S, Shak S, Tang G, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol 2006;24:3726-34.
24. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
25. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92.
26. Simon R, Paik S, Hayes D. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009; 101:1446-52.
27. Simon R. The use of genomics in clinical trial design. Clin Cancer Res 2008;14:5984-93.
28. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-34.
29. Taube SE, Clark GM, Dancey JE, McShane LM, Sigman CC, Gutman SI. A perspective on challenges and issues in biomarker development and drug and biomarker codevelopment. J Natl Cancer Inst 2009;101:1453-63.
30. U.S. Food and Drug Administration, Center for Devices and Radiological Health and Center for Biologics Evaluation and Research. Draft guidance for industry, clinical laboratories, and FDA staff: in vitro diagnostic multivariate index assays. July 26, 2007 [cited April 5, 2010]. Available from: http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/ GuidanceDocuments/ucm071455.pdf.
31. U.S. Department of Health and Human Services, Report of the Secretary's Advisory Committee on Genetics, Health, and Society. U.S. system of oversight of genetic testing: a response to the charge of the Secretary of Health and Human Services. April 2008 [cited April 5, 2010]. Available from: http://oba.od.nih. gov/oba/SACGHS/reports/SACGHS-oversight-report.pdf.
32. Genentech, Inc. Citizen petition: regulation of in vitro diagnostic tests. Submitted December 5, 2008 [cited March 26, 2010]. Available from: http://www.regulations.gov/search/Regs/contentStreamer?objectId= 09000064807d4a7e&disposition=attachment&content Type=pdf.
33. Institute of Medicine of the National AcademiesCommittee on Health Research and the Privacy of Health Information. Beyond the HIPAA privacy rule: enhancing privacy, improving health through research. Washington, DC: National Academies Press; 2009.
34. Biomarkers Definitions Working Group. Biomarkers and surrogate end points: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
35. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, and Center for Devices and Radiological Health. Guidance for industry: pharmacogenomic data submissions. March 2005 [cited March 26, 2010]. Available from: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm126957.pdf.